What question did this study set out to answer?

To compare the incidence of major adverse cardiovascular events between dapagliflozin and empagliflozin in patients with heart failure with reduced ejection fraction.

June 28, 2026British Journal of Clinical Pharmacology

Comparative effectiveness of dapagliflozin vs . empagliflozin on major adverse cardiovascular events in patients with heart failure with reduced ejection fraction: A real‐world prospective cohort study

View Full Paper

Ask AI

Bookmark

Authors

THTuong Le Trong HuynhCan Tho University HTHien Dieu TranCan Tho University PPPhong Thanh PhamCan Tho University

Discussion

Member takes

Implication

Randomized trial compares major adverse cardiovascular events in HFrEF patients, suggesting dapagliflozin is more effective.

Key Points

To compare the incidence of major adverse cardiovascular events between dapagliflozin and empagliflozin in patients with heart failure with reduced ejection fraction.
Prospective cohort study with 1231 HFrEF patients at Can Tho Central General Hospital.
Patients were prescribed either dapagliflozin (622) or empagliflozin (609) as part of optimized guideline-oriented therapy.
Primary outcome focused on major adverse cardiovascular events, analyzed using propensity score matching and multivariable logistic regression.
Dapagliflozin was associated with lower odds of MACE (adjusted OR 0.46; 95% CI [0.30, 0.67]; p < 0.001).
Hospitalization for heart failure was significantly lower with dapagliflozin (8.7% vs. 14.9%; adjusted OR 0.52; 95% CI [0.33, 0.80]; p = 0.003).
Dapagliflozin showed lower corrected all-cause mortality (2.1% vs. 4.1%; p = 0.048).

Cite This Study

Huynh et al. (2026) studied this question.

synapsesocial.com/papers/6a40ba2161bb0a67205c62ac https://doi.org/10.1002/bcp.70654

View Full Paper

Ask AI

Bookmark

Comparative effectiveness of dapagliflozin vs . empagliflozin on major adverse cardiovascular events in patients with heart failure with reduced ejection fraction: A real‐world prospective cohort study

Discussion

Member takes

Implication

Key Points

Cite This Study

Comparative effectiveness of dapagliflozin vs . empagliflozin on major adverse cardiovascular events in patients with heart failure with reduced ejection fraction: A real‐world prospective cohort study

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider